Target intelligence / Profile preview

Alpha-actinin-4 mRNA 3' untranslated region (ACTN4 mRNA 3' UTR)

Target
ACTN4 mRNA 3' UTR
Molecular classification
RNA, Untranslated region, Regulatory element
01

Overview

The Alpha-actinin-4 (ACTN4) mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the ACTN4 transcript that governs the stability and translation efficiency of the encoded protein (NCBI Gene ID: 81). ACTN4 is a non-muscle actin-binding protein involved in cell motility, cytoskeleton organization, and nuclear signaling (UniProt KB: O43707). The 3' UTR contains multiple binding sites for microRNAs, such as miR-124, miR-16, and miR-27a, which typically bind to suppress translation or induce mRNA degradation (PubMed: 23536449, 25670303). In many human cancers, ACTN4 is overexpressed due to the loss of these regulatory microRNAs, promoting tumor progression, metastasis, and epithelial-mesenchymal transition. Consequently, the ACTN4 mRNA 3' UTR is an emerging therapeutic target for RNA-based interventions, including antisense oligonucleotides and microRNA mimics, aimed at reducing ACTN4 levels in oncogenic contexts. Beyond oncology, ACTN4 is essential for the structural integrity of kidney podocytes, and its dysregulation is associated with focal segmental glomerulosclerosis (PubMed: 15504155). Therapeutic development focusing on this region must balance the inhibition of cancer spread with the maintenance of essential physiological functions in the kidney.

Other names
ACTN4 3'-UTRAlpha-actinin-4 3'-UTRACTN4 3' untranslated regionACTN4 mRNA 3' regulatory region
02

Mechanism of action

RNA interference or antisense-mediated degradation of ACTN4 mRNA to reduce protein expression levels by targeting specific sequences within the 3' untranslated region.

03

Biological functions

Post-transcriptional regulationmRNA stability regulationTranslation regulationCell migrationCytoskeleton organization
04

Disease associations

CancerFocal segmental glomerulosclerosisMetastasisBreast cancerLung cancerColorectal cancer
05

Safety considerations

Off-target effects of RNA-based therapiesPotential podocyte toxicity in the kidney due to ACTN4's role in renal filtrationDelivery vehicle-related toxicity (e.g., lipid nanoparticle immunogenicity)Disruption of normal actin cytoskeleton dynamics in non-target tissues
06

Interacting drugs

Antisense oligonucleotides

2 more in the full profile.

07

Biomarkers

ACTN4 protein expression levelsACTN4 mRNA levelsmiR-124 expression levelsmiR-16 expression levels

Beyond the preview

Go deeper on Alpha-actinin-4 mRNA 3' untranslated region (ACTN4 mRNA 3' UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-actinin-4 mRNA 3' untranslated region (ACTN4 mRNA 3' UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call